CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
B	v::ALK	Fusion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Crizotinib	Shaw et al., 2011
B	KIT	Exon 9 Mutation	Predictive	Supports	Sensitivity/Response	Gastrointestinal Stromal Tumor	Sunitinib	Heinrich et al., 2008
D	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	GDC-0879,Dactolisib	Coffee et al., 2013
C	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Gastrointestinal Neuroendocrine Tumor	Trametinib,Vemurafenib,Dabrafenib	Klempner et al., 2016
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Hurvitz et al., 2013
C	v::ROS1	Fusion	Predictive	Supports	Sensitivity/Response	Bronchiolo-alveolar Adenocarcinoma	Crizotinib	Bergethon et al., 2012
C	TFG::ROS1	Fusion	Predictive	Supports	Sensitivity/Response	Inflammatory Myofibroblastic Tumor	Crizotinib	Lovly et al., 2014
A	FIP1L1::PDGFRA	Fusion	Predictive	Supports	Sensitivity/Response	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Imatinib	Cools et al., 2003
D	PIK3CA	H1047R	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Dactolisib	Engelman et al., 2008
B	TP53	Mutation	Prognostic	Supports	Poor Outcome	Chronic Lymphocytic Leukemia		el Rouby et al., 1993
E	BRAF	D594A	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Sorafenib,Mitogen-Activated Protein Kinase Kinase Inhibitor	Heidorn et al., 2010
D	PTEN	Loss	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab,PI3K/BET Inhibitor LY294002	Nagata et al., 2004
E	BRAF	D594V	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Trametinib,Sorafenib	Heidorn et al., 2010
E	BRAF	K483M	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Sorafenib,Mitogen-Activated Protein Kinase Kinase Inhibitor	Heidorn et al., 2010
C	BRAF	L597S	Predictive	Supports	Sensitivity/Response	Skin Melanoma	MEK Inhibitor REC-4881	Dahlman et al., 2012
D	BRAF	K601E	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Vemurafenib,Trametinib	Dahlman et al., 2012
C	BRAF	L597V	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Trametinib	Falchook et al., 2012
B	KIT	Amplification	Predictive	Supports	Resistance	Mucosal Melanoma	Imatinib	Hodi et al., 2013
D	PTEN	Mutation	Predictive	Supports	Resistance	Head And Neck Squamous Cell Carcinoma	Taselisib	Zumsteg et al., 2016
D	NF1	Mutation	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Sirolimus,Mirdametinib	Maertens et al., 2013
B	TP53	Mutation	Prognostic	Supports	Poor Outcome	Chronic Lymphocytic Leukemia		Gonzalez et al., 2011
D	PIK3CA	Mutation	Predictive	Supports	Sensitivity/Response	Head And Neck Squamous Cell Carcinoma	Radiation Therapy,Taselisib	Zumsteg et al., 2016
D	PTEN	Mutation	Predictive	Supports	Sensitivity/Response	Cancer	Ipatasertib	Lin et al., 2013
D	PIK3CA	Mutation	Predictive	Supports	Sensitivity/Response	Stomach Cancer	Capivasertib	Li et al., 2013
D	PTEN	Loss	Predictive	Supports	Sensitivity/Response	Cancer	Capivasertib	Davies et al., 2012
D	PIK3CA	Mutation	Predictive	Supports	Sensitivity/Response	Cancer	Capivasertib	Davies et al., 2012
D	PIK3CA	H1047R	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab,Capivasertib	Davies et al., 2012
D	PIK3CA	H1047R	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Capivasertib,Lapatinib	Davies et al., 2012
B	ASXL1	Mutation	Prognostic	Supports	Poor Outcome	Myelofibrosis		Patel et al., 2015
D	NRAS	Mutation	Predictive	Supports	Sensitivity/Response	Melanoma	Binimetinib	Thumar et al., 2014
C	RET	Overexpression	Predictive	Supports	Sensitivity/Response	Papillary Adenocarcinoma	Sunitinib	Jones et al., 2010
C	PML::RARA	Fusion	Predictive	Supports	Sensitivity/Response	Acute Promyelocytic Leukemia	Tretinoin	Welch et al., 2011
D	PTEN	Mutation	Predictive	Supports	Sensitivity/Response	Prostate Adenocarcinoma	Alpelisib,PI3Kbeta Inhibitor AZD8186,Enzalutamide	Schwartz et al., 2015
B	BRCA1	Loss-of-function	Prognostic	Supports	Poor Outcome	Prostate Cancer		Castro et al., 2013
B	BRCA2	Loss-of-function	Prognostic	Supports	Poor Outcome	Prostate Cancer		Castro et al., 2013
C	FLT3	Overexpression	Predictive	Supports	Sensitivity/Response	B-cell Adult Acute Lymphocytic Leukemia	Sunitinib	Griffith et al., 2016
B	BRCA1	Mutation	Predictive	Supports	Sensitivity/Response	Ovarian Carcinoma	Platinum Compound	Pennington et al., 2014
B	BRCA2	Mutation	Predictive	Supports	Sensitivity/Response	Ovarian Carcinoma	Platinum Compound	Pennington et al., 2014
B	BRCA1	Mutation	Predictive	Supports	Sensitivity/Response	Ovarian Carcinoma	Platinum Compound	Pennington et al., 2014
B	BRCA2	Mutation	Predictive	Supports	Sensitivity/Response	Ovarian Carcinoma	Platinum Compound	Pennington et al., 2014
D	PTEN	V317FS	Predictive	Supports	Sensitivity/Response	Skin Melanoma	MEK Inhibitor CI-1040,Akt Inhibitor MK2206	Turajlic et al., 2014
D	RB1	Loss-of-function	Predictive	Supports	Resistance	Breast Cancer	Palbociclib	Dean et al., 2010
D	GNAQ	Q209P	Predictive	Supports	Resistance	Skin Melanoma	PLX4720	Turajlic et al., 2014
D	MTOR	M2327I	Predictive	Does Not Support	Resistance	Breast Cancer	Sirolimus,RapaLink-1	Rodrik-Outmezguine et al., 2016
B	BRAF	V600E	Prognostic	Supports	Poor Outcome	Colorectal Cancer		Amaki-Takao et al., 2016
C	FLT3	D835H	Predictive	Supports	Resistance	Acute Myeloid Leukemia	Sorafenib	Baker et al., 2013
B	RUNX1	Mutation	Prognostic	Supports	Poor Outcome	Acute Myeloid Leukemia		Gaidzik et al., 2016
B	ATM	Underexpression	Prognostic	Supports	Poor Outcome	Chronic Lymphocytic Leukemia		Starostik et al., 1998
C	MET	Amplification	Predictive	Supports	Sensitivity/Response	Glioblastoma	Crizotinib	Chi et al., 2012
C	B2M	S14FS	Predictive	Supports	Resistance	Skin Melanoma	Pembrolizumab	Zaretsky et al., 2016

Page 36 of 96

Previous Next